AR060732A1 - USES OF ESCITALOPRAM - Google Patents

USES OF ESCITALOPRAM

Info

Publication number
AR060732A1
AR060732A1 ARP070101874A ARP070101874A AR060732A1 AR 060732 A1 AR060732 A1 AR 060732A1 AR P070101874 A ARP070101874 A AR P070101874A AR P070101874 A ARP070101874 A AR P070101874A AR 060732 A1 AR060732 A1 AR 060732A1
Authority
AR
Argentina
Prior art keywords
escitalopram
isobenzofurancarbonitrile
fluorphenyl
inn
diminished
Prior art date
Application number
ARP070101874A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR060732A1 publication Critical patent/AR060732A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se relaciona con el uso del compuesto escitalopram (nombre de INN), es decir, (S)-1-[3-(di-metil-amino)propil]-1-(4-fluorfenil)-1,3- dihidro-5-isobenzofurancarbonitrilo, o una sal farmacéuticamente aceptable del mismo, para la preparacion de un medicamento para mejorar la cognicion en un trastorno en que los procesos cognitivos están disminuidos.This is related to the use of the compound escitalopram (name of INN), that is, (S) -1- [3- (di-methyl-amino) propyl] -1- (4-fluorphenyl) -1,3- dihydro-5-isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for improving cognition in a disorder in which cognitive processes are diminished.

ARP070101874A 2006-05-02 2007-04-30 USES OF ESCITALOPRAM AR060732A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02

Publications (1)

Publication Number Publication Date
AR060732A1 true AR060732A1 (en) 2008-07-10

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101874A AR060732A1 (en) 2006-05-02 2007-04-30 USES OF ESCITALOPRAM

Country Status (15)

Country Link
EP (1) EP2026793A2 (en)
JP (1) JP2009535367A (en)
KR (1) KR20090009820A (en)
CN (1) CN101426494A (en)
AR (1) AR060732A1 (en)
AU (1) AU2007245983A1 (en)
BR (1) BRPI0710230A2 (en)
CA (1) CA2651002A1 (en)
EA (1) EA200870491A1 (en)
IL (1) IL194628A0 (en)
MX (1) MX2008013911A (en)
NO (1) NO20085009L (en)
TW (1) TW200812993A (en)
WO (1) WO2007124757A2 (en)
ZA (1) ZA200808632B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944030B1 (en) 2002-08-22 2018-08-01 Sumitomo Dainippon Pharma Co., Ltd. Agent for treatment of schizophrenia
AU2004249621B2 (en) 2003-06-23 2009-08-06 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co Method of in vivo screening of therapeutic agent for memory/learning dysfunction by schizophrenia
EP2185155B1 (en) * 2007-08-03 2017-10-04 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
JP7149287B2 (en) 2016-12-20 2022-10-06 エルテーエス ローマン テラピー－ジステーメ アーゲー Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
BR112020026099A2 (en) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag transdermal therapeutic system containing asenapine
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient
CN109464436A (en) * 2019-01-10 2019-03-15 高智玉 Citalopram or escitalopram combine the application in the compound preparation of preparation treatment phrenoblabia class disease with Quetiapine respectively

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK213290D0 (en) * 1990-09-06 1990-09-06 Lundbeck & Co As H TREATMENT OF CEREBROVASCULAR DISORDERS
SE9803157D0 (en) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (en) * 1998-09-16 1998-09-16 Astra Ab A new composition
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
AU1810501A (en) * 2000-12-01 2002-06-11 Be Able Llc Behavior chemotherapy
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP1578738B1 (en) * 2002-12-23 2008-03-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
BRPI0413750A (en) * 2003-09-04 2006-10-24 Lundbeck & Co As H use of loxapine or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and kit
KR20080075113A (en) * 2005-10-14 2008-08-14 하. 룬트벡 아크티에 셀스카브 Stable pharmaceutical formulations containing escitalopram and bupropion
US7569605B2 (en) * 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram

Also Published As

Publication number Publication date
EA200870491A1 (en) 2009-04-28
CA2651002A1 (en) 2007-11-08
CN101426494A (en) 2009-05-06
JP2009535367A (en) 2009-10-01
TW200812993A (en) 2008-03-16
IL194628A0 (en) 2009-08-03
ZA200808632B (en) 2009-12-30
EP2026793A2 (en) 2009-02-25
AU2007245983A1 (en) 2007-11-08
MX2008013911A (en) 2008-11-12
WO2007124757A2 (en) 2007-11-08
NO20085009L (en) 2008-12-16
KR20090009820A (en) 2009-01-23
BRPI0710230A2 (en) 2011-08-02
WO2007124757A3 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
AR060732A1 (en) USES OF ESCITALOPRAM
CL2008003822A1 (en) Compounds derived from n1- (2-thiazolyl) -1,2-dicarboxamide pyrrolidine; preparation procedure; pharmaceutical composition; pharmaceutical combination; and use for the treatment of diseases ameliorated by phosphatidylinositol-3-kinase inhibition, such as cancer.
CL2007002197A1 (en) COMPOUNDS DERIVED FROM INDOL; PREPARATION PROCEDURE; INTERMEDIARY COMPOUND; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF MELLITUS DIABETES, DIABETIC RETINOPATHY, HYPERGLUCEMIA, HYPERL
NO20091260L (en) Combination therapy for diabetes mellitus
CL2008002228A1 (en) Compounds derived from imidazopyridinones, tlr7 agonist; preparation procedure; intermediate compounds; pharmaceutical composition comprising them; and use in viral, bacterial and fungal infections.
UY31554A1 (en) NEW INHIBITORS OF ACETIL COENZIMA TO CARBOXYLASE AND USES IN OBESITY TREATMENTS AND MELLITUS DIABETES
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
PE20142371A1 (en) PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINE-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND AN ANTIEPYLEPTIC
CL2011000835A1 (en) Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others.
PA8785401A1 (en) BENCIMIDAZOL DERIVATIVES
CL2012000921A1 (en) Compounds derived from spiropiperidine-methylbenzyloxyphenyl, activators of the rpg-40 receptor; pharmaceutical composition comprising them; and use of the compound to treat diabetes.
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
NI200800176A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF DEPRESSION
CL2012002944A1 (en) Compounds derived from amino-pyrimidines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others.
CL2012002945A1 (en) Compounds derived from amino-pyridazines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others.
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
CL2011002706A1 (en) Compounds derived from 4- (1,3-oxazol-2-yl) -1h-indazole; pharmaceutical composition that includes them; and its uses in the treatment of diseases such as epoc, autoimmune, asthma, among others.
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
CL2007003803A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER, DYSLIPIDEMIA, DIABETES, OBESITY, INFECTION.
EA201692167A1 (en) MODULATORS OF TOLL-SECONDARY RECEPTORS
CL2008001049A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED BENZAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DIABETES, INTOLERANCE TO GLUCOSE, DISLIPIDEMIA, HYPERTENSION, OBESITY.
AR068369A1 (en) N4 XINAFOATE SALT - [(2,2-DIFLUOR-4H-BENZO [1,4] OXAZIN-3-ON) -6-IL] -5-FLUOR-N2- [3- (METHYLAMINOCARBONYLMETHYLENE) -FENYL] 2 , 4-PYRIMIDINDIAMINE "
CL2011000544A1 (en) Compounds derived from benzamide n substituted by heterocycle, cannabinoid receptor ligands; pharmaceutical composition; and its use to treat pain, among other diseases.
CL2011002206A1 (en) Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others.
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.

Legal Events

Date Code Title Description
FB Suspension of granting procedure